Anavex Life Sciences Unveils Encouraging Phase 2/3 Trial Results for Rett Syndrome Treatment; Co-Primary Endpoint, The Clinical Global Impression, Was Not Met.
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and